ALT vs NVO: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ALT and NVO share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ALT and NVO exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Altimmune is a clinical-stage biopharmaceutical company focused on metabolic and liver disease. Its lead candidate, pemvidutide, is a dual agonist of the GLP-1 and glucagon receptors designed to drive weight loss while preserving lean mass and improving liver health. The company has run a Phase 2 obesity program (MOMENTUM) and a Phase 2b MASH program (IMPACT), and reported positive 48-week topline MASH results in December 2025 showing significant improvements in liver fat, weight, and fibrosis markers versus placebo.

Full ALT guide

Novo Nordisk (NVO) is a Danish pharmaceutical company and a global leader in diabetes and obesity care. Its franchise centers on GLP-1 receptor agonists, most notably semaglutide, sold as Ozempic and Rybelsus for type 2 diabetes and as Wegovy for chronic weight management. Novo Nordisk also holds a long-standing leadership position in insulin and broader diabetes therapies, and maintains smaller franchises in rare blood and endocrine disorders. The company is headquartered in Bagsvaerd, Denmark, and is controlled by the Novo Nordisk Foundation through a dual-share structure. US investors typically access it through the NVO American Depositary Receipt listed on the New York Stock Exchange, which represents the Danish B shares. The explosive demand for GLP-1 drugs for both diabetes and weight loss has made Novo Nordisk one of Europe's most valuable companies, while also straining its manufacturing capacity for injectable medicines.

Full NVO guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• ALT drivers: Differentiated GLP-1/glucagon profile; MASH opportunity.
• NVO drivers: GLP-1 obesity and diabetes demand; Pipeline and next-generation candidates.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Altimmune is a single-asset, clinical-stage company with no approved products and no revenue, so a failed or disappointing Phase 3 readout could sharply reduce the stock. For NVO, novo Nordisk is heavily concentrated in a single drug class, so any clinical setback, safety signal, or faster-than-expected competition from Eli Lilly's tirzepatide (Mounjaro, Zepbound) and newer entrants directly threatens the core franchise.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ALT if you believe its drivers more; NVO if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ALT and NVO guides.

ALT. As a pre-revenue biotech, Altimmune cannot be valued on earnings or P/E; its market value reflects the probability-weighted commercial potential of pemvidutide. The roughly $535 million cash position is a key strength because it funds expensive Phase 3 work, but the eventual value depends on trial outcomes and approval, both of which are uncertain.

NVO. Novo Nordisk has historically commanded a premium pharma multiple on the strength of GLP-1 growth and very high margins. The multiple is sensitive to GLP-1 market-share dynamics versus Eli Lilly, supply progress, and US pricing news; disappointing trial data or share loss can compress it quickly. All figures are approximate, are reported in Danish kroner and translated to dollars, and should be verified against the latest filings.

Headline figures (approximate, Q1 2026): ALT shows product revenue None (clinical-stage), cash + short-term investments ~$535 million, lead program Pemvidutide (obesity, MASH), mash stage Phase 3 (PERFORMA) planned H2 2026; NVO shows revenue (ttm) ~$40 billion (approximate, verify; reported in Danish kroner), operating margin ~45% (approximate, verify), net margin ~35% (approximate, verify), glp-1 share of revenue Majority of sales from semaglutide products (approximate).

ALT and NVO are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ALT and NVO exposure against your real portfolio. It is not an investment adviser.